凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海医药2007年半年度报告摘要

公告日期 2007-08-25
股票简称:上海医药 股票代码:601607
股票简称 上海医药 股票代码 600849
上海市医药股份有限公司2007年半年度报告摘要

    1重要提示
    1.1本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    本半年度报告摘要摘自半年度报告全文,报告全文同时刊载于http://www.sse.com.cn。投资者欲了解详细内容,应当仔细阅读半年度报告全文。
    1.2公司部分董事出席董事会会议,副董事长郁庆华先生、独立董事冯正权先生因故未出席会议。
    1.3公司半年度财务报告未经审计。
    1.4、公司董事长钱◇先生、总经理余金琦女士、财务副总监许薇薇女士声明:保证本半年度报告中财务报告的真实、完整。
    2上市公司基本情况
    2.1公司基本情况简介
      股票简称                             上海医药
      股票代码                              600849
                                          董事会秘书
        姓名                                曹伟荣
      联系地址            上海市延安西路1566号龙峰大厦26楼
        电话                            021-52588888
        传真                            021-52586299
      电子信箱                         wrcao@sina.com
    2.2主要财务数据和指标
    2.2.1主要会计数据和财务指标
    单位:元币种:人民币
                                                                                                本报告期末比上年度期末增
                                                本报告期末                上年度期末
                                                                                                           减(%)
     总资产                                         7,030,365,224.95          6,692,759,758.07                               5.04
     所有者权益(或股东权益)                       1,971,407,358.72          1,922,313,310.88                               2.55
     每股净资产(元)                                             4.16                      4.05                               2.55
                                                                                                 本报告期比上年同期增减
                                            报告期(1-6月)               上年同期
                                                                                                            (%)
     营业利润                                          69,173,842.70            79,075,199.63                              -12.52
     利润总额                                          72,825,383.35            79,076,304.73                               -7.90
     净利润                                            55,840,216.53            61,861,598.64                               -9.73
     扣除非经常性损益的净利润                          45,142,005.43            56,247,896.88                             -19.74
     基本每股收益(元)                                           0.12                     0.13                               -9.73
     净资产收益率(%)                                            2.83                     3.22             减少0.39个百分点
     经营活动产生的现金流量净额                       145,034,244.36            58,704,073.31                              147.06
     每股经营活动产生的现金流量
                                                               0.31                      0.12                              147.06
     净额
        注:1、营业利润、利润总额、净利润同比减少的原因:公司持股24.13%的参股企业上海华源长富药业(集团)有限公司上半年亏损影响公司收益-837万元。
        2、经营活动产生的现金流量净额同比增长的原因:公司通过对应收应付账款、应收应付票据的精细化管理以及库存的集约管理、监控,加快了现金周转天数。
        2.2.2非经常性损益项目
        √适用□不适用
        单位:元币种:人民币
                                    非经常性损益项目                                             金额
     处置长期股权投资、固定资产、在建工程、无形资产、其他长期资产产
                                                                                              1,879,191.62
     生的损益
     各种形式的政府补贴                                                                       1,438,057.49
     短期投资损益,但经国家有关部门批准设立的有经营资格的金融机构获
                                                                                              8,175,993.56
     得的短期投资损益除外
     扣除公司日常根据企业会计制度规定计提的资产减值准备后的其他各项
                                                                                               -795,031.57
     营业外收入、支出
     合计                                                                                    10,698,211.10
        2.2.3国内外会计准则差异
        □适用√不适用
        3股本变动及股东情况
        3.1股份变动情况表
        □适用√不适用
        3.2股东数量和持股情况
        单位:股
     报告期末股东总数                                                                                               23,021
     前十名股东持股情况
                                                                                       持有有限售
                                           持股比                      报告期内增                      质押或冻结的股份
          股东名称           股东性质                   持股总数                       条件股份数
                                            例(%)                           减                                 数量
                                                                                            量
     上海市医药(集              国有法
                                             39.69    188,248,134                 0    188,248,134              无
     团)有限公司               人股东
     中国工商银行-华              其他       4.59     21,771,002       21,771,002                             未知
     安中小盘成长股票
     型证券投资基金
     中国农业银行-中
     邮核心优选股票型              其他       4.53      21,481,800      21,481,800                             未知
     证券投资基金
     中国建设银行-华
     夏优势增长股票型              其他       2.30      10,902,947       4,608,508                             未知
     证券投资基金
     中信实业银行-招
     商优质成长股票型              其他       1.77       8,447,442       8,447,442                             未知
     证券投资基金
     兴和证券投资基金              其他       1.66       7,895,281       7,895,281                             未知
     中国工商银行-鹏
     华优质治理股票型
                                   其他       1.44       6,815,061       6,815,061                             未知
     证券投资基金
      (LOF)
     中国建设银行-国
     泰金鼎价值精选混              其他       1.16       5,500,000       5,500,000                             未知
     合型证券投资基金
     中国建设银行-华
     夏红利混合型开放              其他       1.14       5,423,094       5,423,094                             未知
     式证券投资基金
     中国工商银行-申
     万巴黎新动力股票              其他       1.11       5,248,404       5,248,404                             未知
     型证券投资基金
     前十名无限售条件股东持股情况
                                                                           持有无限售
                                 股东名称                                  条件股份数                 股份种类
                                                                                量
     中国工商银行-华安中小盘成长股票型证券投资基金                         21,771,002                        人民币普通股
     中国农业银行-中邮核心优选股票型证券投资基金                           21,481,800                        人民币普通股
     中国建设银行-华夏优势增长股票型证券投资基金                           10,902,947                        人民币普通股
     中信实业银行-招商优质成长股票型证券投资基金                            8,447,442                        人民币普通股
     兴和证券投资基金                                                        7,895,281                        人民币普通股
     中国工商银行-鹏华优质治理股票型证券投资基金(LOF)                       6,815,061                        人民币普通股
     中国建设银行-国泰金鼎价值精选混合型证券投资基金                        5,500,000                        人民币普通股
     中国建设银行-华夏红利混合型开放式证券投资基金                          5,423,094                        人民币普通股
     中国工商银行-申万巴黎新动力股票型证券投资基金                          5,248,404                        人民币普通股
     金盛证券投资基金                                                        5,020,000                        人民币普通股
                                                                          公司前十位股东中,中国建设银行-华夏优势
                                                                          增长股票型证券投资基金、中国建设银行-华
                                                                          夏红利混合型开放式证券投资基金同属华夏基
     上述股东关联关系或一致行动关系的说明                                 金管理公司管理,其他股东之间有无关联关
                                                                          系,或是否属于《上市公司股东持股变动信息
                                                                          披露管理办法》规定的一致行动人,本公司不
                                                                          详。
        3.3控股股东及实际控制人变更情况
        □适用√不适用
        4董事、监事和高级管理人员
        4.1董事、监事和高级管理人员持股变动
        □适用√不适用
        5董事会报告
        5.1主营业务分行业、产品情况表
        单位:元币种:人民币
                                                                                   营业收入比营业成本比
                                                                                                                毛利率比上年同期
    分行业或分产品           营业收入                营业成本         毛利率(%)上年同期增上年同期增
                                                                                                                     增减(%)
                                                                                      减(%)         减(%)
         分行业
    1.工业                    235,837,515.60        177,219,562.46          24.86         -2.43         -5.91增加2.78个百分点
    2.商业                  6,807,894,847.14      6,359,970,728.67           6.58         10.92          9.91增加0.87个百分点
    3.服务业                      596,002.00                               100.00         28.06          0.00
                                                                    -
    小计                    7,044,328,364.74      6,537,190,291.13           7.20         10.42          9.41增加0.86个百分点
    内部抵销                  728,465,309.87        724,600,262.57           0.53         13.39         12.79增加0.53个百分点
    合计                    6,315,863,054.87      5,812,590,028.56           7.97         10.09          9.00增加0.92个百分点
        其中:报告期内,上市公司向控股股东及其子公司销售产品或提供劳务的关联交易金额1611.57万元。
        5.2主营业务分地区情况
                                                 单位:元币种:人民币
          地区               营业收入            营业收入比上年增减(%)
    上海地区                 5,649,798,635.98                             10.68
    安徽地区                    27,527,458.23                            -11.49
    山东地区                   236,054,888.85                             16.29
    浙江地区                 1,108,069,734.28                              8.07
    其他地区                    22,877,647.40                             46.91
    合计                     7,044,328,364.74                             10.42
    内部抵消                   728,465,309.87                             13.39
    合计                     6,315,863,054.87                             10.09
        5.3主营业务及其结构发生重大变化的原因说明
        □适用√不适用
        5.4主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
        □适用√不适用
        5.5利润构成与上年度相比发生重大变化的原因分析
        □适用√不适用
        5.6募集资金使用情况
        5.6.1募集资金运用
        □适用√不适用
        5.6.2变更项目情况
        □适用√不适用
        5.7董事会下半年的经营计划修改计划
        □适用√不适用
        5.8预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及说明
        □适用√不适用
        5.9公司董事会对会计师事务所本报告期“非标准审计报告”的说明
        □适用√不适用
        5.10公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明
        □适用√不适用
        6重要事项
        6.1收购、出售资产及资产重组
        6.1.1收购资产
        □适用√不适用
        6.1.2出售资产
        √适用□不适用
        见“其他重大事项的说明”。
        6.1.3自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况的影响。
        □适用√不适用
        6.2担保事项
        √适用□不适用
        单位:元币种:人民币
                                    公司对外担保情况(不包括对子公司的担保)
                       发生日期                                                                         是否为关联方
      担保对象                                                     担保类                    是否履
                      (协议签署              担保金额                          担保期                   担保(是或
         名称                                                         型                     行完毕
                          日)                                                                               否)
      同济大学
                     2002年3月                                     连带责       2009年
      附属同济                                 542.89                                          否              否
                          5日                                      任担保      12月5日
         医院
     报告期内担保发生额合计                                                                                            0
     报告期末担保余额合计(A)                                                                                    542.89
                                                公司对子公司的担保情况
     报告期内对子公司担保发生额合计                                                                                 8550
     报告期末对子公司担保余额合计(B)                                                                           9570.00
                                        公司担保总额(包括对子公司的担保)
     担保总额(A+B)                                                                                            10112.89
     担保总额占公司净资产的比例                                                                                   5.13%
     其中:
     为股东、实际控制人及其关联方提供担保的金额(C)                                                                   0
     直接或间接为资产负债率超过70%的被担保对象提供的债务
                                                                                                                   9070
     担保金额(D)
     担保总额超过净资产50%部分的金额(E)                                                                             0
     上述三项担保金额合计(C+D+E)                                                                                  9070
        6.3非经营性关联债权债务往来
        √适用□不适用
        单位:万元币种:人民币
                                                   与上市公       上市公司向关联方提供资金           关联方向上市公司提供资金
                     关联方名称
                                                   司的关系
                                                                 发生额             余额             发生额            余额
    上海英达莱置业有限公司                         参股企业              0           2,800.00
    上海医药(集团)有限公司                       控股股东                                      10,000.00            10,000.00
                        合计                                             0           2,800.00    10,000.00            10,000.00
        注:与上海英达莱置业有限公司发生的2800万元系2006年发生的非经营性往来款(详见公司2006年年报)
        6.4重大诉讼仲裁事项
        □适用√不适用
        6.5其它重大事项及其影响和解决方案的分析说明
        6.5.1公司持有其他上市公司发行的股票和证券投资情况
        √适用□不适用
     序    股票代                                 占该公司股                           会计核算
                    简称       持股数量(股)                     初始投资成本(元)
     号      码                                   权比例(%)                              科目
                    复旦                                                              长期股权
     1    HK8231                   139,586,000         19.66%          19,147,723.08
                    张江                                                              投资
                    中国                                                              可供出售
     2    601988                     1,700,000            <1%              7,894,800
                    银行                                                              金融资产
                    工商                                                              可供出售
     3    601398                       931,298            <1%           4,864,169.45
                    银行                                                              金融资产
                    云内                                                              可供出售
     4    000903                       210,000            <1%             3,991,260
                    动力                                                              金融资产
                    宝钢                                                              可供出售
     5    600019                       260,000            <1%             2,919,800
                    股份                                                              金融资产
                    上港                                                              可供出售
     6    600018                       340,000            <1%             2,154,580
                    集团                                                              金融资产
                    交通    101,000+288,504.00                 1,185,235+288,504.00   可供出售
     7    601328                                          <1%
                    银行              (限售)                             (限售)   金融资产
                    龙溪                                                              可供出售
     8    600592                        45,000            <1%                972,765
                    股份                                                              金融资产
                    中西                                                              可供出售
     9    600842                        80,000            <1%                968,960
                    药业                                                              金融资产
                    中国                                                              可供出售
     10   601318                         4,000            <1%                135,200
                    平安                                                              金融资产
                    锦化                                                              可供出售
     11   000818                        10,000            <1%                 85,320
                    氯碱                                                              金融资产
                    百联                                                              可供出售
     12   600631                        65,450            <1%                 65,450
                    股份                                                              金融资产
                    中国                                                              可供出售
     13   601919                         7,000            <1%                 59,360
                    远洋                                                              金融资产
                    中信                                                              可供出售
     14   601998                        10,000            <1%                 58,000
                    银行                                                              金融资产
                    中国                                                              可供出售
     15   601628                         3,000            <1%                 56,640
                    人寿                                                              金融资产
                    连云                                                              可供出售
     16   601008                         4,000            <1%                 19,920
                    港                                                                金融资产
                    东南                                                              可供出售
     17   002135                         1,000            <1%                  9,600
                    网架                                                              金融资产
                    实益                                                              可供出售
     18   002137                           500            <1%                  5,150
                    达                                                                金融资产
     期末持有的其他证券
                                    --                --                           0      --
     投资
     合计                           --                --              44,882,436.53       --
        6.5.2公司持有非上市金融企业、拟上市公司股权的情况
        √适用□不适用
                                     最初投资成本    持股数量     占该公司股权    期末账面价值
              持有对象名称
                                        (元)         (股)         比例(%)          (元)
     上海申银万国证券股份有限公司      20,000,000   20,000,000              <1%      20,000,000
       中国银河证券股份有限公司        50,000,000   10,000,000              <1%      50,000,000
                  小计                                                 -            70,000,000
        6.5.2其他重大事项的说明
        √适用□不适用
        ①公司下属上海华氏制药有限公司(下称:华氏制药)于2007年6月26日在上海与美国Perrigo(百利高)公司签订了医药固体制剂合同制造(OEM)协议(美国Perrigo(百利高)公司是全球最大的贴牌OTC药品生产商之一)。协议约定,华氏制药每年将为Perrigo公司生产制造21.5亿片药品,供货的初始期限为5年。在此基础上,双方还约定继续协商进一步扩大OEM的合作。协议的签署,有助于上海医药形成新的盈利增长点。
        ②  2007年5月15日,公司与日本铃谦株式会社签订了设立医药分销合资企业的协议。决定以上海沪中医药有限公司为基础,以股权转让方式变更设立中日合资上海铃谦沪中医药有限公司。重组后的上海沪中医药有限公司50%股权对应的账面净资产值为3779.6万元,转让对价为13500万元。目前公司正在进一步推进项目报批工作。
        本次合资对公司推进国际化战略,加快医药分销国际化步伐,构筑引进、消化并创新国际医药分销先进理念与模式的平台;加快医药商业模式率先转型,创新盈利结构,提升市场价值;实现医药中高端品种、先进管理模式和增值服务技术等重要经营资源的直接引进,提升核心竞争力;借船出海,逐步开拓海外分销渠道,实现国内外联动均有十分重要的意义。
        ③报告期内,根据公司2006年度股东大会决议,公司决定申请发行一年期短期融资券7亿元,现报批工作正在办理中。短期融资券的发行,有助于公司降低财务费用。
        ④关于上海华源长富药业(集团)有限公司会计处理作重大调整导致我公司权益受损的情况及处理:
        1)问题由来
        上海华源长富(集团)有限公司(下称:华源长富)系我司持有24.13%股权的参股企业,中国华源集团有限公司及其子公司持有该司75.87%股权。
        2007年6月,我司接华源长富通知,该司决定对已经董事会审议通过的2006年度审计报告进行调整,并收到未经该司董事会和股东会审议由该司审计机构岳华会计师事务所有限责任公司2007年5月24日后出具的有保留意见的2006年度审计报告(调整稿)。该审计机构保留意见对华源长富为关联方应收款项6216万元全额计提坏帐准备、对其控股子公司无锡华源发马制药有限公司未出现减值迹象的长期投资4800万元全额计提长期投资减值准备均明确表示无法确认。
        2)公司调查
        为充分维护股东权益,查清事实,2007年7月,我司委托立信会计师事务所有限公司对华源长富2006年度审计报告(调整后)中的保留事项及2007年半年报亏损情况进行了专题调查。
        专题调查报告对华源长富为涉及关联方的6216万元欠款,包括“中国华源集团2003年5月向华源长富借款及利息余额2947万元、安徽华源生物药业有限公司2003年5月向华源长富增资2867万元而同月华源长富又付给该司暂付款余额3200万元、华源长富2003年12月代中国华源集团垫付云峰药业股权转让款138万元(其中2006年度计提69万元坏帐准备)”计提全额减值准备明确指出有失妥当。
        专题调查报告还指出,华源长富做出上述如此重大的财务处理,未经公司董事会的审议批准,且在明知另一方股东持不同意见的情况下,由大股东单方作出决定的处理方式有失妥当。
        3)公司的态度及对2006年报的处理
        公司认为,对华源长富的上述会计处理,该司审计机构和我司审计机构均提出了不同意见。但因华源长富到目前为止仍未改变上述会计处理,故公司在采取进一步措施维护股东权益的同时,按照会计谨慎性原则的要求,对华源长富上述重大会计差错按持股比例进行了追溯调整,并对比较会计报表年初数和上年数作了相应调整,由此影响公司2006年度净利润-29,772,683.42元;影响公司2007年初留存收益-29,772,683.42元,其中影响公司2007年初未分配利润-26,795,415.08元。鉴于上述原因,此项会计处理的最终结果仍可能存在不确定性。
        4)关于华源长富2007年半年报亏损问题。
        华源长富2007年7月正式提交给公司的半年报,表明该司2007年上半年亏损4969万元。对此,立信会计师事务所有限公司专项调查报告指出:在2007年4月27日浙江省杭州市中级人民法院判决的案例中,杭州伽玛公司归还银行借款1500万元本金及利息,华源长富承担相应连带责任,华源长富对此计提了预计负债1500万。因华源长富在这一判例中并未行使其拥有的追索权力,而直接计提了预计负债1500万元,故我司对该笔预计负债不予确认。华源长富为安置职工发生费用近3000万元。
        根据专题调查结果,公司确认华源长富2007年上半年亏损3469万元,故影响公司2007年上半年投资收益-837万元。
        7财务报告
        7.1审计意见
        财务报告                  √未经审计 □审计
        7.2财务报表
                                                                                                                         资产负债表
                                                                                                                 2007年06月30日
                                                                                                                                                                                                     单位:元币种:人民币
                   编制单位:上海市医药股份有限公司
                                                        合并                                            母体                                                                            合并                                             母体
                                                                                                                                       负债和所有者权
               资产
                                                                                                                                    益(或股东权益)
                                        期末余额                年初余额                期末余额                 年初余额                                       期末余额                 年初余额                期末余额                 年初余额
      流动资产:
      货币资金                        686,077,674.74        534,755,148.77          233,892,715.40            152,333,108.39     短期借款                       2,130,510,000.00         2,159,700,000.00       1,874,000,000.00      1,956,000,000.00
      交易性金融资产                  -                                              -                         -                 交易性金融负债                 -                                               -
      应收票据                        55,069,950.67         56,154,513.02           15,656,467.31            29,338,299.40       应付票据                       428,903,405.29           317,135,887.23         417,236,502.47        311,711,443.72
      应收账款                        2,214,920,588.97      1,835,825,992.16        1,048,682,812.53         865,676,291.22      应付账款                       1,963,393,574.77         1,797,318,250.25       758,281,352.06        741,525,896.94
      预付款项                        108,028,720.79        252,767,464.38           85,657,766.05            153,612,852.20     预收款项                       52,034,548.36            158,519,077.69         20,056,904.07         107,886,067.39
      应收利息                        -                     -                       -                         -                  应付职工薪酬                   37,533,944.53            27,656,151.61          1,900,219.23          975,603.43
      应收股利                        1,242,805.32          1,242,805.32                          -           -                  应交税费                       23,036,838.09            19,469,407.35          11,576,483.44         11,324,327.48
      其他应收款                      469,468,329.56        481,335,693.54          879,144,088.04           808,024,782.19      应付利息                       6,079,456.26             6,110,812.27           2,850,406.56          3,268,099.08
      存货                            1,108,749,083.27      1,223,088,393.90        558,240,664.57            669,688,586.33     应付股利                       5,984,018.86             7,151,358.52           -                     -
      一年内到期的非流                -                     -                       -                                            其他应付款                     354,602,343.71           202,382,534.64         226,774,511.12        38,684,638.38
    动资产
                                                                                                                                 一年内到期的非流
      其他流动资产                    -                     -                       -                        -                                                  73,174.98                -
                                                                                                                                 动负债
          流动资产合计                4,643,557,153.32      4,385,170,011.09        2,821,274,513.90         2,678,673,919.73    其他流动负债                   -                        -
      非流动资产:
      可供出售金融资产                27,757,879.45         20,154,220.00           -                                            非流动负债:
      持有至到期投资                  -                     -                                                                    长期借款                       1,240,000.00             1,240,000.00           -                      -
      长期应收款                      50,000,000.00         50,000,000.00           -                                            应付债券                       -                        -                      -                      -
      长期股权投资                    560,487,940.21        560,206,685.16          1,344,994,212.90         1,360,722,680.43    长期应付款                     38,876,058.84            24,671,335.84          31,685,572.04          17,623,857.04
      投资性房地产                    -                     -                                                                    专项应付款                     -                        -                      -                      -
      固定资产                        1,258,284,343.50      1,183,645,869.97        717,370,771.19           697,020,004.56      预计负债                       15,593,299.67            46,061,014.23          11,312,377.78          25,230,000.00
      在建工程                        72,285,494.79         65,285,135.09           1,857,658.00             1,172,498.00        递延所得税负债                 1,170,377.85             2,913,114.45           -
      工程物资                        -                     -                       -                        -                   其他非流动负债                 -                        44,328.13              -
      固定资产清理                    634.36                -                       -                         -                  非流动负债合计                 56,879,736.36            74,929,792.65          42,997,949.82          42,853,857.04
      生产性生物资产                  -                     -                                                                    负债合计                       5,058,957,866.23         4,770,446,447.19       3,355,674,328.77       3,214,229,933.46
                                      -                     -                                                                    所有者权益(或股
      油气资产
                                                                                                                                 东权益):
                                                                                                                                 实收资本(或股
      无形资产                        379,819,427.09        384,810,454.31           64,269,105.23             65,333,816.96                                    474,310,737.00           474,310,737.00         474,310,737.00         C474,310,737.00
                                                                                                                                 本)
      开发支出                        -                     -                             资本公积                          686,787,722.40           686,787,722.40          686,787,722.40         686,787,722.40
      商誉                            -                     -                             减:库存股                                         -                                                -
      长期待摊费用                    11,012,754.79         16,327,785.01              607,280.81             1,261,677.25       盈余公积                          328,837,178.31            328,837,178.31          232,750,929.26        232,750,929.26
      递延所得税资产                  27,159,597.44         27,159,597.44           19,585,079.61            19,585,079.61       未分配利润                        124,545,161.70             84,771,667.00          220,434,904.21          215,690,354.42
      其他非流动资产                  -                     -                             外币报表折算差额                                   -                       -                        -
                                      2,386,808,071.63      2,307,589,746.98 2,148,684,107.74                        2,145,095,756.81       归属于母公司所有
        非流动资产合计                                                                                                                                              1,614,480,799.41 1,574,707,304.71                1,614,284,292.87 1,609,539,743.08
                                                                                                                                   者权益合计
                                                                                                                                     少数股东权益                      356,926,559.31           347,606,006.17                           -
                                                                                                                                       所有者权益(或               1,971,407,358.72 1,922,313,310.88                1,614,284,292.87 1,609,539,743.08
                                                                                                                                      股东权益)合计
                                                                                                                                       负债和所有者权
             资产总计               7,030,365,224.95 6,692,759,758.07 4,969,958,621.64                       4,823,769,676.54益(或股东权益)                       7,030,365,224.95 6,692,759,758.07                4,969,958,621.64 4,823,769,676.54
                                                                                                                                               总计
                   公司法定代表人:钱◇
                                                                            利润表
                                                                      2007年1-6月
                                                                                                                           单位:元币种:人民币
    编制单位:上海市医药股份有限公司
                                                               合并                                           母体
                    项目
                                               本年累计数             同期累计数              本年累计数              同期累计数
      一、营业收入                            6,315,863,054.87       5,737,216,876.41        3,448,310,811.97        3,070,981,704.55
      减:营业成本                            5,812,590,028.56       5,332,703,546.44        3,237,849,117.28        2,919,745,255.39
      营业税金及附加                              9,480,535.69           4,741,855.44            3,592,622.60             -141,554.65
      销售费用                                  233,813,123.17         161,700,882.13          115,085,560.57           57,792,289.20
      管理费用                                  135,498,102.97         126,317,258.53           31,023,955.98           25,772,922.45
      财务费用                                   68,654,086.47          47,341,461.09           56,948,422.87           36,279,347.33
      资产减值损失                                 -194,359.09                       -                       -
      加:公允价值变动收益(损
                                                              -                      -                       -
    失以“-”号填列)
      投资收益(损失以“-”号
                                                 13,152,305.60          14,663,326.85              475,153.27              815,712.33
    填列)
      其中:对联营企业和合营企                                -                      -                       -
    业的投资收益
      二、营业利润(亏损以“-                    69,173,842.70          79,075,199.63            4,286,285.94           32,349,157.16
    ”号填列)
      加:营业外收入                              5,616,209.31           3,829,405.87              853,678.48             107,569.13
      减:营业外支出                              1,964,668.66           3,828,300.77               75,309.93           2,092,031.52
      其中:非流动资产处置损失                                -                      -                       -
      三、利润总额(亏损总额以
                                                 72,825,383.35          79,076,304.73            5,064,654.49           30,364,694.77
    “-”号填列)
      减:所得税费用                             16,985,166.82          17,214,706.09              320,104.70           4,834,742.69
      四、净利润(净亏损以“-
                                                 55,840,216.53          61,861,598.64            4,744,549.79           25,529,952.08
    ”号填列)
    公司法定代表人:钱◇
                                                                                                                                        现金流量表
                                                                                                                                     2007年1-6月
                                                                                                                                                                                                                       单位:元币种:人民币
                                  编制单位:上海市医药股份有限公司
                                                                          合并                                              母体                                      补充资料                                      合并                                           母体
                       项目                                                                                                                              1.将净利润调节为经营活
                                                        本年累计数               同期累计数                本年累计数               同期累计数                                                     本年累计数              同期累计数             本年累计数             同期累计数
                                                                                                                                                        动现金流量:
      一、经营活动产生的现金流                               --                        --                       --                       --               净利润                                       62,690,997.01           61,869,689.26     11,676,702.23          51,097,034.15
    量:
      销售商品、提供劳务收到的                          7,765,511,718.59        6,268,629,271.03          3,897,482,344.04         3,189,786,136.32       加:资产减值准备                         -194,359.09             329,516.11                    -                       -
    现金
                                                                                                                                                          固定资产折旧、油气资
      收到的税费返还                                       50,023,071.08            6,239,094.78             46,451,212.60             4,948,966.56产折耗、生产性生物资产                              22,730,192.16           22,421,551.48     12,783,028.99           2,114,936.76
                                                                                                                                                        折旧
      收到其他与经营活动有关的                                413,027.66           12,134,164.90                            -         11,392,493.55       无形资产摊销                             4,847,899.57           5,009,503.29             797,205.27             452,993.48
    现金
      经营活动现金流入小计                              7,815,947,817.33        6,287,002,530.71          3,943,933,556.64         3,206,127,596.43       长期待摊费用摊销                         6,206,746.22           2,954,224.64           2,018,018.48            1,528,537.75
                                                                                                                                                          处置固定资产、无形资
      购买商品、接受劳务支付的                       7,151,139,626.96          5,755,966,777.47         3,608,019,657.13         3,022,399,075.21产和其他长期资产的损失                           -3,618,752.40             39,351.42              11,455.52                    -
    现金
                                                                                                                                                        (收益以“-”号填列)
      支付给职工以及为职工支付                            156,072,194.07          144,412,137.61             70,191,814.63            63,470,723.16       固定资产报废损失(收                      184,099.29             -188,530.90              1,755.99               11,428.53
    的现金                                                                                                                                              益以“-”号填列)
                                                        153,007,160.45             82,938,052.38             50,604,922.21             2,019,497.99       公允价值变动损失(收
      支付的各项税费                                                                                                                                                                                       -                                             -
                                                                                                                                                        益以“-”号填列)
      支付其他与经营活动有关的                            210,694,591.49          244,981,489.94            109,373,599.77           165,357,751.85       财务费用(收益以                             61,782,934.61           59,610,129.36     50,450,602.10          47,357,028.43
    现金                                                                                                                                                “-”号填列)
                                                     7,670,913,572.97           6,228,298,457.40          3,838,189,993.74         3,253,247,048.21       投资损失(收益以
      经营活动现金流出小计                                                                                                                                                                       -20,008,096.08          -14,018,334.36          -7,412,315.71         -26,382,794.40
                                                                                                                                                        “-”号填列)
      经营活动产生的现金流量净                            145,034,244.36           58,704,073.31            105,743,562.90           -47,119,451.78       递延所得税资产减少                               -                                             -
    额                                                                                                                                                    (增加以“-”号填列)
      二、投资活动产生的现金流                               --                        --                       --                       --               递延所得税负债增加                      -1,742,736.60                                          -
    量:                                                                                                                                                  (减少以“-”号填列)
                                                             381,233.60            83,096,991.19                            -         68,096,991.19       存货的减少(增加以
      收回投资收到的现金                                                                                                                                                                         114,338,850.63          105,070,842.63         111,447,461.76          90,069,178.13
                                                                                                                                                        “-”号填列)
                                                                                                                                                          经营性应收项目的减少
      取得投资收益收到的现金                               13,365,809.49           40,257,086.21             16,203,620.80            22,028,268.04                                              -256,598,285.89         -83,423,575.91        -215,046,775.06         -12,473,379.55
                                                                                                                                                        (增加以“-”号填列)
      处置固定资产、无形资产和                             16,235,773.40            7,143,391.58                168,607.84             6,864,800.00       经营性应付项目的增加                   154,414,754.93         -100,970,293.71         139,016,423.33              -200,894,415.06
    其他长期资产收回的现金净额                                                                                                                            (减少以“-”号填列)
      处置子公司及其他营业单位                                           -                                                  -                             其他                                             -                      -                      -                       -
    收到的现金净额
      收到其他与投资活动有关的                                  8,370.41            1,812,549.78                            -                        -    经营活动产生的现金流                   145,034,244.36                58,704,073.31    105,743,562.90         -47,119,451.78
    现金                                                                                                                                                量净额
                                                                                                                                                         2.
                                                         29,991,186.90            132,310,018.76             16,372,228.64            96,990,059.23         不涉及现金收支的重大
      投资活动现金流入小计                                                                                                                                                                               --                     --                     --                      --
                                                                                                                                                        投资和筹资活动:
      购建固定资产、无形资产和                             29,832,927.83          100,605,124.49              8,726,489.88            85,254,799.28       债务转为资本                                             -                                              -
    其他长期资产支付的现金
                                                                                                                                                          一年内到期的可转换公
      投资支付的现金                                       13,000,862.70            1,429,006.18                            -                        -                                                             -                                              -
                                                                                                                                                        司债券
      取得子公司及其他营业单位                                           -                         -                        -                             融资租入固定资产                                         -                                              -
    支付的现金净额
      支付其他与投资活动有关的                                                                                                                           3.
                                                               11,533.61                           -                        -                        -      现金及现金等价物净变                         --                     --                     --                      --
    现金                                                                                                                                                动情况:
      投资活动现金流出小计                                 42,845,324.14          102,034,130.67              8,726,489.88            85,254,799.28       现金的期末余额                          686,077,674.74         593,658,613.72          233,892,715.40          248,068,115.75
      投资活动产生的现金流量净                            -12,854,137.24           30,275,888.09              7,645,738.76            11,735,259.95       减:现金的期初余额                      534,755,148.77         314,205,621.01          152,333,108.39           68,278,196.15
    额
      三、筹资活动产生的现金流                               --                        --                       --                       --               加:现金等价物的期末                                     -                       -                      -                       -
    量:                                                                                                                                                余额
                                                                                                                                                          减:现金等价物的期初
      吸收投资收到的现金                                                 -                         -                        -                        -                                                             -                       -                      -                       -
                                                                                                                                                        余额
                                                                                                                                                          现金及现金等价物净增
      取得借款收到的现金                                 -29,190,000.00            263,646,979.67          -82,000,000.00           250,000,000.00                                                151,322,525.97         279,452,992.71           81,559,607.01          179,789,919.60
                                                                                                                                                        加额
      收到其他与筹资活动有关的                           120,583,063.72                            -       100,000,000.00                            -
    现金
      筹资活动现金流入小计                                91,393,063.72            263,646,979.67           18,000,000.00           250,000,000.00
      偿还债务支付的现金                                                 -                         -                        -                        -
      分配股利、利润或偿付利息                            67,507,418.56             73,533,056.44           49,829,694.65            34,825,888.57
    支付的现金
      支付其他与筹资活动有关的                             3,420,959.32               -359,108.08                           -                        -
    现金
      筹资活动现金流出小计                                70,928,377.88             73,173,948.36           49,829,694.65            34,825,888.57
      筹资活动产生的现金流量净                           20,464,685.84           190,473,031.31            -31,829,694.65           215,174,111.43
    额
      四、汇率变动对现金及现金                            -1,322,266.99                            -                        -                        -
    等价物的影响
      五、现金及现金等价物净增                          151,322,525.97           279,452,992.71             81,559,607.01           179,789,919.60
    加额
      加:期初现金及现金等价物                          534,755,148.77           314,205,621.01            152,333,108.39            68,278,196.15
    余额
      六、期末现金及现金等价物                           686,077,674.74            593,658,613.72          233,892,715.40           248,068,115.75
    余额
                                  公司法定代表人:钱◇
                                                                                                                         合并所有者权益变动表
                                                                                                                                   2007年1-6月
                                编制单位:上海市医药股份有限公司
                                                                                                                                                                                                                     单位:元币种:人民币
                                                                                              本年累计数                                                                                                                 同期累计数
                                             实收资本                                                                                                                  实收资本
                  项目                                                                减:                                                                                                                       减:
                                                                   资本公积                       盈余公积             未分配利润           所有者权益合计                                   资本公积                         盈余公积             未分配利润          所有者权益合计
                                              (或股本)                             库存股                                                                              (或股本)                               库存股
      一、上年年末余额                  474,310,737.00         679,129,582.40           -      331,814,446.65         270,199,300.87       1,755,454,066.92        474,310,737.00         678,818,701.09                  326,878,455.22        277,560,785.87         1,757,568,679.18
      加:会计政策变更                                           7,658,140.00                                        -158,632,218.79        -150,974,078.79                                    31,052.11                                       -161,773,946.99          -161,742,894.88
      前期差错更正                                                                              -2,977,268.34         -26,795,415.08         -29,772,683.42                                                                -5,826,400.00        -23,305,600.00           -29,132,000.00
      二、本年年初余额                  474,310,737.00         686,787,722.40           -      328,837,178.31          84,771,667.00       1,574,707,304.71        474,310,737.00         678,849,753.20           -      321,052,055.22         92,481,238.88         1,566,693,784.30
      三、本年增减变动金额                             -                     -          -                    -         39,773,494.70          39,773,494.70                       -                     -          -                    -        51,097,034.15            51,097,034.15
    (减少以“-”号填列)
      (一)净利润                                                                                                     39,773,494.70          39,773,494.70                                                                                      51,097,034.15            51,097,034.15
      (二)直接计入所有者权                           -                     -          -                    -                      -                       -                     -                     -          -                    -                      -                       -
    益的利得和损失
     1.可供出售金融资产公                                                                                                                                  -                                                                                                                          -
    允价值变动净额
     2.权益法下被投资单位
    其他所有者权益变动的影                                                                                                                                  -                                                                                                                          -
    响
     3.与计入所有者权益项                                                                                                                                  -                                                                                                                          -
    目相关的所得税影响
     4.其他                                                                                                                                                -                                                                                                                          -
      上述(一)和(二)小计                           -                     -          -                    -        39,773,494.70           39,773,494.70                       -                     -          -                    -        51,097,034.15            51,097,034.15
      (三)所有者投入和减少                           -                     -          -                    -                      -                       -                     -                     -          -                    -                      -                       -
    资本
     1.所有者投入资本                                                                                                                                       -                                                                                                                          -
     2.股份支付计入所有者                                                                                                                                  -                                                                                                                          -
    权益的金额
     3.其他                                                                                                                                                -                                                                                                                          -
      (四)利润分配                                   -                     -          -                    -                      -                       -                     -                     -          -                    -                      -                       -
     1.提取盈余公积                                                                                                                                        -                                                                                                                          -
     2.对所有者(或股东)                                                                                                                                  -                                                                                                                          -
    的分配
     3.其他                                                                                                                                                -                                                                                                                          -
      (五)所有者权益内部结                           -                     -          -                    -                      -                       -                     -                     -          -                    -                      -                       -
    转
     1.资本公积转增资本                                                                                                                                    -                                                                                                                          -
    (或股本)
     2.盈余公积转增资本                                                                                                                                    -                                                                                                                          -
    (或股本)
     3.盈余公积弥补亏损                                                                                                                                    -                                                                                                                          -
     4.其他                                                                                                                                                -                                                                                                                          -
      四、本年年末余额                  474,310,737.00        686,787,722.40            -     328,837,178.31         124,545,161.70        1,614,480,799.41        474,310,737.00        678,849,753.20            -     321,052,055.22         143,578,273.03         1,617,790,818.45
                                                                                                                         母体所有者权益变动表
                                                                                                                                   2007年1-6月
                                编制单位:上海市医药股份有限公司
                                                                                                                                                                                                                     单位:元币种:人民币
                                                                                           本年累计数                                                                                                                  同期累计数
                项目                      实收资本                                 减:                                                                              实收资本
                                                                资本公积                         盈余公积            未分配利润           所有者权益合计                                    资本公积           减:         盈余公积              未分配利润          所有者权益合计
                                           (或股本)                              库存股                                                                               (或股本)                               库存股
      一、上年年末余额                474,310,737.00        679,129,582.40                  235,728,197.60          401,402,095.47       1,790,570,612.47        474,310,737.00        678,818,701.09                    234,850,377.25         376,227,515.57        1,764,207,330.91
      加:会计政策变更                                        7,658,140.00                                        -158,916,325.97         -151,258,185.97                                    31,052.11                                        -135,907,270.49         -135,876,218.38
      前期差错更正                                                                            -2,977,268.34         -26,795,415.08         -29,772,683.42                                                                 -5,826,400.00         -23,305,600.00          -29,132,000.00
      二、本年年初余额                474,310,737.00        686,787,722.40            -     232,750,929.26         215,690,354.42        1,609,539,743.08        474,310,737.00         678,849,753.20            -     229,023,977.25         217,014,645.08        1,599,199,112.53
      三、本年增减变动金额                           -                     -          -                    -          4,744,549.79           4,744,549.79                       -                     -           -                    -                      -                       -
    (减少以“-”号填列)
      (一)净利润                                                                                                    4,744,549.79           4,744,549.79                                                                                                                             -
      (二)直接计入所有者                           -                     -          -                    -                      -                       -                     -                     -           -                    -                      -                       -
    权益的利得和损失
     1.可供出售金融资产                                                                                                                                  -                                                                                                                           -
    公允价值变动净额
     2.权益法下被投资单
    位其他所有者权益变动                                                                                                                                  -                                                                                                                           -
    的影响
     3.与计入所有者权益                                                                                                                                  -                                                                                                                           -
    项目相关的所得税影响
     4.其他                                                                                                                                              -                                                                                                                           -
      上述(一)和(二)小                           -                     -          -                    -          4,744,549.79           4,744,549.79                       -                     -           -                    -                      -                       -
    计
      (三)所有者投入和减                           -                     -          -                    -                      -                       -                     -                     -           -                    -                      -                       -
    少资本
     1.所有者投入资本                                                                                                                                     -                                                                                                                           -
     2.股份支付计入所有                                                                                                                                  -                                                                                                                           -
    者权益的金额
     3.其他                                                                                                                                              -                                                                                                                           -
      (四)利润分配                                 -                     -          -                    -                      -                       -                     -                     -           -                    -                      -                       -
     1.提取盈余公积                                                                                                                                      -                                                                                                                           -
     2.对所有者(或股                                                                                                                                    -                                                                                                                           -
    东)的分配
     3.其他                                                                                                                                              -                                                                                                                           -
      (五)所有者权益内部                           -                     -          -                    -                      -                       -                     -                     -           -                    -                      -                       -
    结转
     1.资本公积转增资本                                                                                                                                  -                                                                                                                           -
    (或股本)
     2.盈余公积转增资本                                                                                                                                  -                                                                                                                           -
    (或股本)
     3.盈余公积弥补亏损                                                                                                                                  -                                                                                                                           -
     4.其他                                                                                                                                              -                                                                                                                           -
      四、本年年末余额                474,310,737.00        686,787,722.40            -     232,750,929.26          220,434,904.21       1,614,284,292.87        474,310,737.00        678,849,753.20             -      229,023,977.25         217,014,645.08        1,599,199,112.53
        公司法定代表人:钱◇
        7.3报表附注
        7.3.1如果出现会计政策、会计估计变更和会计差错更正的,说明有关内容、原因和影响数。
        √适用□不适用
        1.根据财政部财会[2006]3号《关于印发<企业会计准则第1号-存货>等38项具体准则的通知》,公司从2007年1月1日起,执行新《企业会计准则》;并根据《企业会计准则第38号-首次执行企业会计准则》所规定的5-19条相关内容,对财务报表项目进行了追溯调整。上列各项对报表的影响如下:
                                         符合预计负债确 符合预计负债
                       长期投权投资差                                                  可供出售金
           项目                          认条件的辞退补 确认条件的重    企业合并         所得税         其他
                           额                                           融资产
                                         偿             组业务
    对资本公积的影响                                                   7,658,140.00
    对2007年初留存收益的影
                          -25,531,270.75 -40,219,424.00 -2,502,499.85 -91,337,287.36                   -19,927,777.88
    响                                                                                  20,886,041.05
    其中:对2007年初未分配-25,531,270.75 -40,219,424.00 -2,502,499.85 -91,337,287.36                   -19,927,777.88
    利润的影响                                                                          20,886,041.05
    对本年度净利润的影响
    2.对上年度重大会计差错进行更正:
    公司持股24.13%的联营单位上海华源长富药业(集团)有限公司(以下简称华源长富)于2007年6月寄送给上海医药的华源长富2006年度审计报告(由岳华会计师事务所有限责任公司于2007年5月24日后出具)中所附财务报表的2006年净利润比其2007年3月提供的2006年度经审计会计报表数调减了123,384,514.78元,其中主要是:
    (一)对关联方中国华源集团有限公司2,947万元、安徽华源生物药业有限公司3,200万元的其他应收款计提了全额减值准备;
    (二)对子公司无锡华源长富发马制药有限公司的股权投资4800万元计提了全额减值准备;
    (三)为无锡华源长富发马制药有限公司担保承担连带责任计提预计负债1,220万。
    公司认为,对华源长富的上述会计处理,岳华会计师事务所有限公司出具的审计报告(调整后)和立信会计师事务所有限公司出具的专项调查报告均提出了不同意见。但因华源长富至今仍无改变上述会计处理的意愿,故公司在采取进一步措施维护股东权益的同时,按照会计谨慎性原则,对华源长富上述重大会计差错按所持股权比例进行了追溯调整,并对比较会计报表年初数和上年数作了相应调整,由此影响公司2006年度净利润-29,772,683.42元;影响公司2007年初留存收益-29,772,683.42元,其中影响公司2007年初未分配利润-26,795,415.08元。鉴于华源长富上述会计处理的最终结果仍存在不确定性,公司维权工作在继续,尽管公司按会计谨慎性原则本次进行了追溯调整,但不排除公司2007年年报对上述计提影响金额转回的可能。
    7.3.2如果会计报表合并范围未发生重大变化的,说明原因和影响数。
    √适用□不适用
    与上年相比本年新增合并单位10家:
    1、上海马陆制药有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    2、上海医药商务网络有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    3、上海华氏医药储运有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    4、香港思富有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    5、上海市医药股份有限公司池州华氏公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    6、上海金山医药药材有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    7、安徽华氏医药有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    8、上海制药(苏丹)有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    9、上海华天广告有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。
    10、上海市一大药房有限公司:系公司控制之子公司,根据2006年颁布的企业会计准则,本年纳入合并范围。

    董事长:钱◇
    上海市医药股份有限公司
    2007.8.25
数据加载中...
prevnext
手机查看股票